Phase I Program

Note: Other Phase 1 Studies may be open at the Knight, please click here to view

No Known Mutations

- IRB# 19388 A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors
- IRB 21194 study A phase 1 study of SGN-CD228A in select advanced solid tumors
- IRB# 21464 A Phase I Study of mRNA-2752 for Intratumoral Injection Alone and in Combination with Immune Checkpoint Blockade
- IRB# 21766 A Phase I/b study of GEN-001 in Combination with Avelumab in Patients with Advanced Solid Tumors Who Have Progressed during or after Treatment with Anti-PD-(L1) therapy
- IRB# 22082 A Phase 1b, Open-label, Dose-escalation and Dose-expansion Study to Evaluate Camidanlumab Tesirine (ADCT-301) as Monotherapy or in Combination in Patients With Selected Advanced Solid Tumors
- IRB# 22760 Study of Magrolimab in Participants With Solid Tumors
- IRB# 23157 Study of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies
- IRB# 23236 Study of SGN-STNV in Advanced Solid Tumors
- IRB 24483 Phase 1 study of BAL0891 as monotherapy and in combination with chemotherapy in patients with advanced solid tumors
- IRB 24493 A Phase 1/2a, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of IMT-009 in Patients with Advanced Solid Tumors
- IRB 24494 A Phase 1 Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies (CERTIS1)
- IRB 24635 An open-label, master protocol to study Datopotamab Deruxtecan (Dato-DXd) alone and in combination with anticancer agents in patients with advanced/metastatic solid tumors
- IRB 24649 Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

Key:
- Open for Enrollment
- In Development
- Enrollment on Hold

10/31/2022

http://www.ohsu.edu/research/rda/so/knight.php
Phase I Program

Note: Other Phase 1 Studies may be open at the Knight, please click here to view

IRB 21548  
A Phase 1 Study of AMG 650 in Subjects With Advanced Solid Tumors

IRB 21810  
A Phase 1-2 Study of ASTX029 in Subjects With Advanced Solid Tumors

IRB# 17674  
LOxo-195 in fusion-NTRK (previously treated) solid tumors

IRB# 16676  
BLU-667 in thyroid cancer, non-small cell lung cancer and advanced solid tumors

IRB# 18164  
A Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity

IRB 21998  
A Phase 1/2 Open-label study to evaluate PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation

IRB 21998  
A Phase 1/2 Open-label study to evaluate PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation

IRB 22223  
A Phase 1a/1b Open-label Study to Evaluate PY159 as a Single Agent and In Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

Key

- Open for Enrollment
- In Development
- Enrollment on Hold

10/31/2022

http://www.ohsu.edu/research/rda/so/knight.php
<table>
<thead>
<tr>
<th>Project ID</th>
<th>Project Title</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>IRB 22863</td>
<td>A Study of PY314 in Subjects With Advanced Solid Tumors</td>
<td>Trem2 expression phase 2</td>
</tr>
<tr>
<td>IRB 22925</td>
<td>A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours</td>
<td>Microsatellite Stable (MSS) colorectal, ovarian, and endometrial</td>
</tr>
<tr>
<td>IRB 22902</td>
<td>A Phase 2, SUBPROTOCOL OF DAY101 MONOTHERAPY FOR PATIENTS WITH RECURRENT, PROGRESSIVE, OR REFRACTORY SOLID TUMORS WITH ACTIVATING BRAF GENE FUSION</td>
<td>Advanced solid tumor that has progressed after all available standard therapy or for which standard therapy has proven to be ineffective, or if no further standard, therapy exists</td>
</tr>
<tr>
<td>IRB 22966</td>
<td>A Phase 1 Study of 23ME-00610 in Patients With Advanced Solid Malignancies</td>
<td>Solid tumors with a BRAF fusion alteration</td>
</tr>
<tr>
<td>IRB 25023</td>
<td>A Phase 1/2, First-in-Human Study of DCC-3116 as Monotherapy and in Combination with RAS/MAPK Pathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations</td>
<td>Solid tumors with MAPK pathway mutation</td>
</tr>
</tbody>
</table>